| Dendreon Wins Approval for World's First Personalized Cancer Treatment The Burrill Report submits: By Michael FitzhughDendreon (DNDN) won U.S. Food and Drug Administration approval for Provenge, the world's first cancer vaccine on April 29, boosting the company's once-lowly share price and igniting a new line of revenue potentially worth $1 billion to $2 billion annually. Complete Story » seekingalpha.com |
Weikang Bio-Tech Could Be a Winning Investment While the the GeoTeam's shift in strategy to increase its exposure to US stocks is still intact, select ChinaHybrids may still be able to perform in 2010 by bucking the short-term trend of subpar EPS growth issues caused by recent dilution activities.One stock on our list that may fit this bill is Weikang Bio-Tech Group (WKBT.OB).Complete Story » seekingalpha.com |
Gilead Misses, Trims Outlook Zacks.com submits: Gilead Sciences (GILD) reported second quarter fiscal 2010 earnings of 81 cents, a penny below the Zacks Consensus, but well above the year-earlier earnings of 65 cents. Revenues increased 17% to $1.93 billion. Foreign exchange (Fx) fluctuations adversely impacted revenues by $16.3 million. Revenues Product sales increased 15% to $1.81 billion driven by growth in sales of antiviral products such as Atripla (growth of 26% to $715.8 million), Truvada (growth of 6% to $641.7 million) and Viread (growth of 11% to $176.2 million).Complete Story » seekingalpha.com |
Genzyme Sells Genetics Unit Genzyme is selling its genetic-testing business to Laboratory Corp. of America Holdings for $925 million. online.wsj.com |
Endo's Latest Acquisition Builds Out Pain Franchise, Generics Lineup The Burrill Report submits: By Michael FitzhughEndo Pharmaceuticals (ENDP) is buying the privately-held generic pain medications giant Qualitest from Apax Partners for about $1.2 billion. If approved by regulators, the deal would broadly expand the number of Endo's generic medicines under active FDA review and would bolster its portfolio of generic pain management drugs, giving it deeper access to the $15 billion U.S. pain medication market.Complete Story » seekingalpha.com |